Madrigal Pharmaceuticals
MDGL
84 hedge funds and large institutions have $320M invested in Madrigal Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 32 increasing their positions, 25 reducing their positions, and 12 closing their positions.
84% more call options, than puts
Call options by funds: $9.41M | Put options by funds: $5.12M
28% more capital invested
Capital invested by funds: $249M → $320M (+$70.8M)
28% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 25
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
0% more funds holding
Funds holding: 84 → 84 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.04M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.11M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$3.03M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$2.65M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$5.46M |
| 2 |
QF
QVT Financial
New York
|
-$4.14M |
| 3 |
Goldman Sachs
New York
|
-$1.96M |
| 4 |
PA
Perceptive Advisors
New York
|
-$1.9M |
| 5 |
Jane Street
New York
|
-$1.41M |
MDGL Hedge Fund Activity: Q3 2013 in Review
84 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q3 2013, worth a combined $320M — up 28% from $249M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new MDGL positions and 12 closed out — a net gain of 1 holder — while 32 added to existing stakes and 25 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $8.04M. The largest seller was Baker Bros. Advisors, cutting an estimated $5.46M.
- 84 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q3 2013, unchanged from Q2 2013.
- Funds reported $320M of Madrigal Pharmaceuticals stock for Q3 2013, up 28% quarter-over-quarter.
- 13 funds opened new Madrigal Pharmaceuticals positions in Q3 2013 and 12 closed out, a net change of +1 holder.
- The largest Madrigal Pharmaceuticals buyer in Q3 2013 was Fidelity Investments, an estimated $8.04M added.
- The largest Madrigal Pharmaceuticals seller in Q3 2013 was Baker Bros. Advisors, an estimated $5.46M sold.
Based on aggregated 13F filings for Q3 2013.